MINERALYS THERAPEUTICS INC

Mineralys Therapeutics CEO’s July 13, 2026 block sale shows a rule‑based divestment amid strong Phase IIa safety data for its aldosterone synthase inhibitor, MST‑001, and pending orphan drug approval.

Rule 10b5‑1 trades by Mineralys Therapeutics’ CMO reveal a disciplined insider strategy, not a sudden confidence shift – monitor pipeline milestones and liquidity events for future price moves.

Mineralys Therapeutics insider trading: CMO Rodman Malcom’s 10b‑5‑1 plan shows neutral, low‑risk buy‑sell activity, signaling no imminent price change but highlighting upcoming Phase 2 trial impact.

Mineralys CEO’s latest 10b‑5‑1 sale shows a disciplined plan amid strong market momentum, with institutional buying counterbalancing insider divestiture.

RA Capital’s latest 3 % stake in Mineralys Therapeutics signals growing confidence in its aldosterone‑inhibitor pipeline, amid a 14.6 % weekly rally and strong investor sentiment.

Mineralys insider trading shows steady, plan‑driven moves by CMO Malcom, reinforcing management confidence while highlighting the company’s niche biopharma focus and valuation upside amid financial volatility.

Mineralys insider confidence rises as Chief Commercial Officer Warren Eric locks in 38,400 shares via RSUs, signaling bullish hopes for its ASI pipeline amid market volatility.

RA Capital’s recent 6,200‑share purchase of Mineralys Therapeutics signals growing institutional conviction in the company’s promising aldosterone synthase inhibitor pipeline, offering investors potential upside and share‑price stability as Phase II…

Mineralys insider buying by CMO Rodman Malcom signals confidence amid a 17.4% monthly dip—what this means for investors and future ASI milestones.

Explore how Mineralys Therapeutics’ insider trades reveal confidence in its aldosterone‑inhibitor pipeline and what it means for reimbursement, tech adoption, and investor strategy.